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Long-term infections with viruses permit the generation of variants that evolve specific growth advantages in certain tissues and may
show altered disease potentials. The selection of such variants is influenced by the host tissue and often involves virus–receptor interactions.
Here we report studies of receptor usage by several lymphocytic choriomeningitis virus (LCMV) isolates that expressed different disease
patterns. Consistent with our previous studies, we found that, with one exception, multiple LCMV variants that cause suppression of immune
responses bound with high affinity to their cellular receptor a-dystroglycan (a-DG) and were dependent on a-DG for entry and infection. The
exception also bound strongly to a-DG but was not dependent on a-DG for entry and infection. In contrast, those variants of LCMV that do
not suppress the immune response either displayed low or no binding affinity for a-DG and used alternative receptors in addition to or instead
of a-DG for entry and infection. For all a-DG binding variants, a-DG represents the preferred receptor in DG-expressing cells, as soluble a-
DG blocked their infection of DG-deficient cells, indicating that binding of a-DG to the viral glycoprotein (GP) at the virion surface
interferes with the GP’s interaction with the alternative receptor. Biochemical characterization of the alternative receptor(s) for LCMV
indicated that they are either protein(s) or protein-bound entities.
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Lymphocytic choriomeningitis virus (LCMV) is the
prototypic member of the arenavirus family (Buchmeier et
al., 2001; Oldstone, 2002). Its bisegmented negative-strand
genome consists of two single-stranded RNA species, a
larger segment encoding the virus polymerase (L) and a
small zinc finger motif protein (Z), and a smaller segment
encoding the virus nucleoprotein (NP) and glycoprotein
(GP) precursor (GPC). GPC is processed into the peripheral
GP1 and the transmembrane GP2 by the protease SKI-1/S1P
(Beyer et al., 2003; Buchmeier and Oldstone, 1979; Kunz et
al., 2003). GP1 is implicated in receptor binding (Borrow
and Oldstone, 1992; Parekh and Buchmeier, 1986) and GP20042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.05.009
* Corresponding author. Division of Virology, Department of Neuro-
pharmacology, The Scripps Research Institute, 10550 North Torrey Pines
Road, IMM-6, La Jolla, CA 92037.
E-mail address: stefanku@scripps.edu (S. Kunz).is structurally similar to the fusion active membrane prox-
imal portions of the GPs of other enveloped viruses (Gal-
laher et al., 2001). Upon receptor binding, arenavirus virions
are internalized by uncoated vesicles and released into the
cytoplasm by a pH-dependent membrane fusion step (Bor-
row and Oldstone, 1994; Di Simone and Buchmeier, 1995;
Di Simone et al., 1994). Persistent infection with LCMV
permits the emergence of variants that have a growth
advantage in particular cell types. Closely related variants
of the same LCMV strain can have very profound differ-
ences, causing unique disease phenotypes that correlate with
the tissue from which they were isolated. In mice persis-
tently infected with LCMV ARM53b, brain isolates gener-
ally exhibit the disease phenotype of the parental virus,
causing an acute infection, which is efficiently cleared by
the host’s antiviral CD8+ cytotoxic T lymphocytes (CTLs).
In contrast, the majority (>95%) of variants isolated from
lymphoid organs cause a persistent infection accompanied
by a generalized immunosuppression (Ahmed and Oldstone,
1988; Ahmed et al., 1984; Evans et al., 1994; Sevilla et al.,
Table 1
LCMV isolates used in this study
Isolate IS P Tropism aa GP1 260
ARM53b   RP F
CD4-1   RP F
CD8-4   RP F
cl-13 + + MZ/WP L
PBL364 + + MZ/WP L
PBL673 + + MZ/WP L
WE54 + + MZ/WP L (S153)
WE22   RP L (F153)
The variants CD4-1 and CD8-4 were isolated from CD4 and CD8 cells
from perforin ko mice after 24 days of infection with ARM53b (Sevilla et
al., 2000). LCMV cl-13 is a spleen isolate of an adult BALB/WEHI mouse
infected persistently since birth with ARM53b (Ahmed et al., 1984).
PBL364 and PBL673 were isolated from peripheral blood lymphocytes
(PBLs) of perforin ko mice persistently infected with LCMVARM53b for 7
months (Sevilla et al., 2000). WE2.2 is derived from WE54 and differs from
WE54 by only one amino acid exchange, S153F in GP1 (Teng et al., 1996).
The phenotype of the immunosuppressive LCMV variants cl-13, PBL364,
PBL673, and WE54 is as follows: they induce immunosuppression (IS+),
cause persistent infection (P+), and show a tropism for the marginal zone
(MZ) and the white pulp (WP) of the spleen. The variants ARM53b, CD4-
1, CD8-4, and WE2.2 are non-immunosuppressive (IS), are cleared by the
host immune system (P), and infect the red pulp (RP) of the spleen. The
amino acid in position 260 of GP1 (aa GP1260) is indicated. For the
variants WE54 and WE2.2, which both contain an L in position 260 of
GP1, the amino acid at position 153 of GP1 is indicated in brackets.
S. Kunz et al. / Virology 325 (2004) 432–445 4332000; Smelt et al., 2001). Sequence analysis of a large
number of immunosuppressive variants consistently
revealed an amino acid exchange F260L or F260I (F:
wild-type CTL producers, L and I, variants that cause
immunosuppression) in GP1. As the selection of variants
is influenced by the host cell or tissue, it likely involves
virus–receptor interactions.
Several members of the arenavirus family use a-dystro-
glycan (a-DG) as a cellular receptor, including the Old
World arenaviruses LCMV, Lassa fever virus (LFV), and
Mobala as well as Clade C New World arenaviruses (Cao et
al., 1998; Spiropoulou et al., 2002). a-DG is a ubiquitously
expressed, highly versatile cell surface receptor that pro-
vides a molecular link between the extracellular matrix
(ECM) and the actin-based cytoskeleton and plays a critical
role in cell-mediated assembly of basement membranes
(Henry and Campbell, 1999; Winder, 2001). Recent studies
revealed a striking and consistent correlation between a-DG
binding affinity, tissue tropism, and pathological potential of
LCMV (Sevilla et al., 2000; Smelt et al., 2001). Immuno-
suppressive LCMV strains and variants containing an L or I
at position 260 of GP1 bind a-DG with high affinity,
replicate preferentially in the marginal zone of the white
pulp of the spleen, and infect >75% of a-DG+ CD11c+ and
DEC 205+ dendritic cells (DCs) (Sevilla et al., 2000). As a
consequence of infection, DCs are unable to act as antigen-
presenting cells and thus fail to generate an anti-viral T and
B cell immune response, resulting in a generalized immu-
nosuppression. In contrast, LCMV strains and variants with
lower (2–3 logs less) binding affinity for a-DG localize
primarily to the red pulp of the spleen, show only limited
infection (<10%) of CD11c+ and DEC 205+ DCs, and
generate an effective and efficient antiviral T cell response
that clears the acute virus infection. Selection of LCMV
variants over time in lymphoid and other organs reveals
strong selective pressure for an aliphatic amino acid in
position 260 of GP and high a-DG binding affinity (Evans
et al., 1994; Sevilla et al., 2000).
Findings reported here revealed that DG (/) mouse
embryonic stem (ES) cells, which are refractory to infection
by most LCMVisolates, can be infected to a certain extent by
some LCMV variants (Smelt et al., 2001). The susceptibility
of this cell type to some LCMV isolates in the absence of a
characterized receptor indicates the existence of alternative
receptors. The existence of such alternative receptors for
LCMV may be important regarding the disease potential of
these viruses as well as shedding light on clade B NewWorld
arenaviruses like Machupo, Junin, Guanarito, and Sabia that
do not use a-DG as their receptor (Spiropoulou et al., 2002).
We investigated the receptor usage of several LCMV isolates
with different disease potential. Consistent with previous
studies, immunosuppressive LCMV variants bound a-DG
with high affinity and critically depended on a-DG for
infection. However, one of these variants tested showed
strong binding to a-DG but no dependence on a-DG for
infection, representing a novel receptor-binding phenotype ofLCMV. Concerning non-immunosuppressive LCMV var-
iants, which showed either low or no binding affinity to a-
DG, all were able to use alternative receptors in addition or
instead of a-DG. We found that in DG-expressing cells, a-
DG represents the preferred receptor for all a-DG binding
variants and that competitive binding with soluble a-DG
interferes with the interaction of the viral GP with the
alternative receptor. Biochemical characterization indicates
that the alternative receptors for LCMV are either protein(s)
or protein-bound entities.Results
LCMV isolates show either high, low, or no binding affinity
to a-dystroglycan
For studies of receptor usage by different LCMV isolates,
we selected the immunosuppressive LCMV variants clone-
13 (cl-13), WE54, PBL364, and PBL673, and the non-
immunosuppressive LCMV variants ARM53b, CD4-1,
CD8-4, and WE2.2, whose origin, disease phenotype, and
tropism in the spleen are detailed in Table 1. a-Dystroglycan
(a-DG) binding of the variants was quantitatively analyzed
in an ELISA-format binding assay. Purified viruses were
immobilized in microtiter plates and binding of biotinylated
a-DG determined. With immunosuppressive variants, half-
maximal binding was observed at 0.5–2 nM a-DG (Fig.
1A). In contrast, a-DG binding to non-immunosuppressive
viruses ARM53b, CD4-1, and CD8-4 was not saturable with
Fig. 1. LCMV isolates show either high, low, or no binding affinity to a-dystroglycan. (A) Binding of biotinylated a-DG to the LCMV variants: purified
viruses were immobilized in microtiter plates and incubated with the indicated concentrations of biotinylated a-DG. Bound biotinylated a-DG was detected
with peroxidase-conjugated streptavidin in a color reaction using ABTS substrate. OD (405) was recorded in an ELISA reader. For the determination of specific
binding, background binding to BSA was subtracted (mean F SD; n = 3). (B) Neutralization of LCMV infection with soluble a-DG: the LCMV variants
indicated were incubated with 0, 1, 5, 20, 100, and 400 nM of a-DG (full symbols) or DGFc1 (empty symbols) for 2 h on ice. The inoculum was then added to
3T6 mouse fibroblasts for 45 min. Cells were washed and incubated for 16 h. LCMV infection was assessed by immunofluorescence staining for LCMV NP.
Data shown are mean percentages of triplicates of infected cells FSD.
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specific binding to a-DG (Fig. 1A). As anticipated by their
different a-DG binding affinities, 1–4 nM of soluble a-DG
was sufficient to achieve 50% inhibition of infection by the
immunosuppressive variants but >100 nM was required for
50% neutralization of ARM53b, CD4-1, and CD8-4 (Fig.
1B). As anticipated because LCMV WE2.2 did not bind to
a-DG, this variant was not neutralized by soluble a-DG. As
a control protein, we used DGFc1, which represents a
transcriptional fusion of amino acids 30–181 of a-DG with
the Fc moiety of human IgG1 and does not bind to LCMV
(Kunz et al., 2001). None of the LCMV variants was
significantly neutralized by up to 400 nM DGFc1 (Fig.
1B), demonstrating the specific blocking of infection by
soluble a-DG. Together, these data demonstrate that the
LCMV isolates fall into three categories of a-DG binding
phenotypes: high-affinity binders with an estimated Kd in
the low nM range (cl-13, WE54, PBL673, and PBL364),
low-affinity binders with Kd >100 nM (ARM53b, CD4-1,
and CD8-4), and a nonbinder (WE2.2).All LCMV isolates contain similar amounts of fully
processed GP
The strikingly different binding affinities of immunosup-
pressive and non-immunosuppressive LCMV variants for a-
DG (Fig. 1) are likely due to structural differences in the
receptor-binding sites of their glycoproteins (GPs). In addi-
tion, different concentrations of GP in the virion envelope or
differences in its proteolytic processing may influence the
virus–receptor interaction. To address potential differences
in GP concentrations in the envelopes of these variants, we
quantitatively assessed the ratios of GP to nucleoprotein
(NP), which is a component of the ribonucleoprotein (RNP)
core of the virion. Purified viruses were immobilized in
microtiter plates and the GP/NP ratios in their virions were
determined by ELISA using monoclonal antibodies (mAbs)
83.6 anti-LCMVGP2 (Weber and Buchmeier, 1988) and 113
anti-LCMV NP (Buchmeier et al., 1981), which recognize
GP2 and NP, respectively, of a wide range of arenaviruses.
All variants displayed GP/NP ratios within the same order
S. Kunz et al. / Virology 325 (2004) 432–445 435of magnitude (Fig. 2A). To assess potential differences in
the proteolytic processing of the GPs of the LCMV variants
studied, viral proteins were examined by Western-blot using
mAb 83.6, which recognizes the GP precursor (GPC) as
well as processed GP2 (Kunz et al., 2003). All LCMV
variants contained exclusively fully processed GP in their
envelope (Fig. 2B). These data demonstrate that all LCMV
isolates contain similar amounts of fully processed GP. The
>100-fold different binding affinities of immunosuppressive
and non-immunosuppressive LCMV variants for a-DG
(Fig. 1) are therefore likely due to structural differences in
the receptor-binding sites of their GPs.
Some LCMV isolates can use other receptors than a-DG for
cell entry
To analyze the dependence of infection by the LCMV
variants on a-DG, we used DG (/) mouse embryonic
stem (ES) cells and the corresponding heterozygous DG
(+/) parental line (Henry and Campbell, 1998). In a first
set of experiments, DG (/) and DG (+/) ES cells were
incubated with virus and infection assessed after 24 and 48
h by detection of LCMV NP. The immunosuppressive
variants cl-13 WE54 and PBL673 showed little infection
of DG (/) ES cells after 24 and 48 h, indicating a strong
dependence of infection on a-DG (Fig. 3). In contrast,
significant infection of DG (/) ES cells at 24 h postin-
fection was observed with the immunosuppressive variant
PBL364. Although ARM53b, CD4-1, and CD8-4 showed
<10% infection of DG (/) ES cells after 24 h, >50% of
cells were infected after 48 h. As previously reported (SmeltFig. 2. All LCMV isolates contain similar amounts of fully processed GP. (A) R
LCMV variants indicated, three independent preparations were analyzed for each v
of microtiter plates and probed with mAb 83.6 anti-GP2 for the detection of GP. F
X-100 and subsequently incubated with mAb 113 anti-LCMV NP. Primary antib
reaction using ABTS substrate. OD (405) was measured using an ELISA reader (n
the average OD (405) of the GP2 signal was divided by the average OD (405) of
FSD. (C) Examination of viral GPs by Western-blot: equal amounts of virus were
and transferred to nitrocellulose. Membranes were probed with mouse mAb 83.6 (a
detection. The positions of mature GP2 and the GP-precursor GPC are indicated.et al., 2001), the non-immunosuppressive variant WE2.2 did
not depend on a-DG for infection. To exclude the possibil-
ity that the differential infection of DG (/) and DG (+/)
ES cells was due to factors not related to a-DG deficiency,
we reconstituted DG expression in DG (/) ES cells. For
this purpose, we infected DG (/) ES cells with adeno-
viral (AdV) vectors containing wild-type DG or the a-DG
deletion mutant DGH (DH30-S485), which is deficient in
virus binding (Kunz et al., 2001). Within 48 h after AdV-
mediated gene transfer, which resulted in >70–80% of
transfected cells expressing heterologous protein, cells were
infected with the LCMV variants. Infection was assessed
after 24 and 48 h as described above. The susceptibility of
DG (/) ES cells transfected with wild-type DG to
infection with the LCMV variants was similar to the one
of DG (+/) cells (Fig. 3). The lower infection rates
observed with the DG-reconstituted DG (/) ES cells
when compared to DG (+/) ES are likely because <80% of
the cells express DG at the time point of LCMV infection.
As expected, transfection of DG (/) cells with the
nonbinding DG mutant DGH had no significant effect on
susceptibility to virus infection. These data indicate that the
reduced infection of DG (/) ES cells by some LCMV
variants is due to lack of a-DG-mediated entry and not
caused by a block in a later step of viral replication or gene
expression. To assess the role of a-DG on the kinetics of
infection, we infected DG (/) and DG (+/) ES cells
with a selected subset of LCMV variants (cl-13, WE54,
PBL364, ARM53b, and WE2.2) and quantified infection at
12, 24, 36, and 48 h postinfection (Fig. 4). Consistent with
the data presented in Fig. 3, the variant WE2.2, which doesatios of GP2/NP in LCMV isolates: to determine the GP2/NP ratios in the
ariant. Equal amounts of purified virus were immobilized in triplicate wells
or the detection of NP, virions were briefly permeabilized with 0.1% Triton-
odies were detected with anti-mouse IgG coupled to peroxidase in a color
= 3F SD). GP2/NP ratios were calculated for each preparation individually:
the NP signal. Data shown are mean GP2/NP ratios from three preparations
solubilized in SDS-PAGE sample buffer, proteins separated by SDS-PAGE,
nti-LCMVGP2) and a peroxidase-conjugated anti-mouse IgG using ECL for
Fig. 3. Some LCMV isolates can use other receptors than a-DG for cell entry. DG ( / ) ES cells were transfected with AdV vectors containing either wild-
type DG (DG ( / ) ES cells + AdV DG wt) or DGH (DG ( / ) ES cells + AdV DGH). Untreated DG ( / ) and DG (+/ ) ES cells were cultured in
parallel. Forty hours after AdV-mediated gene transfer, cells were infected with the indicated LCMV variants at a MOI of 1. Infection levels were assessed after
24 h (black bars) and 48 h (white bars) by immunofluorescence staining with LCMV NP-specific mAb 113. Triplicate samples were counted for each virus and
cell line at each time point. Data shown are mean percentages of infected cells F SD.
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infection kinetics in both cell types. Although the variant
PBL364 infects both cell types efficiently, the presence of
a-DG facilitates infection. Infection of DG (/) ES cells
with ARM53b is significantly delayed when compared toFig. 4. Infection kinetics of DG (/) and DG (+/) ES cells with LCMV variant
cl-13, PBL364, WE54, ARM53b, and WE2.2 at MOI of 1. The percentages of infe
staining with LCMV NP-specific mAb 113. Data shown are mean percentages othe infection of DG (+/) ES cells, indicating an important
role of a-DG in infection with this variant. As expected
based on the strong dependence on a-DG for infection (Fig.
3), the variants cl-13 and WE54 show little infection in DG
(/) cells, even after prolonged incubation times.s. DG (/) and DG (+/) ES cells were infected with the LCMV variants
cted cells were assessed after 0, 12, 24, 36, and 48 h by immunofluorescence
f triplicate samples FSD.
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alternative receptors
Though the a-DG-binding LCMV variants PBL364,
ARM53b, CD4-1, and CD8-4 can use alternative receptors
for cell entry, they infect DG (+/) ES cells more efficiently
than DG (/) ES cells (Figs. 3 and 4), suggesting that a-DG
facilitates infection. The ability of the glycoproteins (GPs) of
these variants to recognize both a-DG and the alternative
receptor may allow these variants to use both receptor
systems at the same time. Alternatively, binding of the viral
GP to a-DG may interfere with its ability to interact with
alternative receptor molecules present at the surface of DG-
expressing cells. To distinguish between these two possibil-
ities, we tested the ability of soluble a-DG to block the
infection of DG (+/) and DG (/) ES cells by the LCMV
variants PBL364, ARM53b, CD4-1, and CD8-4, all of which
show dual receptor specificity. As a control protein, we used
the nonbinding a-DG-Fc fusion protein DGFc1. The results
obtained with the neutralization of infection of DG (+/) ES
cells with a-DG and DGFc1 (Fig. 5) were comparable with
the results obtained with the neutralization of infection of 3T6
fibroblasts (Fig. 1B). Infection of DG (/) ES cells by
PBL364, ARM53b, CD4-1, and CD8-4 was significantly
blocked by soluble a-DG, but not DGFc1 (Fig. 5). Low
nanomolar concentrations of a-DG were sufficient to block
infectionwith the high-affinity binding variant PBL364while
>100 nM a-DG was needed to achieve significant reduction
of infection of DG (/) ES cells by the low-affinity binders
ARM53b, CD4-1, and CD8-4. Consistent with the previous
results, soluble a-DG had no effect on the infection of
DG (/) ES cells with WE2.2 (data not shown). This
correlation between the inhibitory concentrations of a-DG
and the a-DG binding affinity indicates that binding of
S. Kunz et al. / ViroFig. 5. Binding of LCMVGP to a-DG blocks its interaction with alternative recepto
200, and 400 nM of a-DG (a-DG) or 0, 10, 50, 100, 200, and 400 nM of DGFc1 (D
(+/) ES cells or DG (/) ES cells for 45 min. Cells were washed and incubated
described in Fig. 1B. Data shown are mean percentages of triplicates of infectedsoluble a-DG to the GP at the virion surface interferes
with the GP’s ability to interact with alternative receptor
molecules present on DG (/) ES cells.
ARM53b, PBL364, CD4-1, and CD8-4 bind to at least
partially identical alternative receptors that are distinct
from the one(s) used by WE2.2
Next, we addressed the question whether ARM53b,
PBL364, CD4-1, CD8-4, and WE2.2 use identical or
different receptor molecules to infect DG (/) ES cells.
To this end, we blocked DG (/) and DG (+/) ES cells
with a large excess of UV-inactivated LCMV ARM53b or
WE2.2 before infection with the live LCMV variants
PBL364, ARM53b, CD4-1, CD8-4, and WE2.2. The block-
ing virus was produced in BHK21 cells, purified from cell
culture supernatant by ultracentrifugation on a renografin
gradient, and subjected to UV inactivation as described by
Bachmann et al. (1994). Inactivation of the virus was
verified by plaque assay and immunofluorescence. To
address the possibility that an unknown component may
have been co-purified from the BHK21 supernatants that
may interfere with the assay, we subjected supernatants of
mock-infected BHK21 cells to the same purification and
inactivation procedure and used the resulting fractions as a
negative control. In DG (/) ES cells, previous blocking
with UV-inactivated ARM53b, but not the control superna-
tant, resulted in significant reduction of the subsequent
infection with ARM53b, PBL364, CD4-1, and CD8-4, but
not WE2.2 (Fig. 6). Preincubation of DG (+/) ES cells
with UV-inactivated ARM53b affected only the subsequent
infection with ARM53b, CD4-1, and CD8-4, but not
PBL364 and WE2.2. The absence of a significant reduction
in case of PBL364 is likely due to its much higher bindingrs. The LCMV variants indicated were incubated with either 0, 10, 50, 100,
GFc1) for 2 h on ice. The inoculum (MOI = 3) was then added to either DG
for 16 h. LCMV infection was assessed by immunofluorescence staining as
cells FSD.
Fig. 6. ARM53b, PBL364, CD4-1, and CD8-4 bind to at least partially identical alternative receptors that are distinct from the one(s) used by WE2.2. 2  103
DG (+/) and DG (/) ES cells per well were cultured in 96-well plates and blocked with either 100 Al 108 pfu/ml UV-inactivated purified LCMVARM53b
(black bars), WE2.2. (gray bars) or with purified control supernatant (white bars). For blocking, the ratio of (inactivated) infectious particles per cell was 5000:
1. After incubation for 2 h at 4 jC, cells were infected with live LCMVARM53b, PBL364, CD4-1, CD8-4, and WE2.2 at a MOI of 1 in the presence of 108
pfu/ml UV-inactivated virus or control supernatant (100 Al/well) for 45 min. Infection was assessed after 16 h by immunofluorescence staining for LCMV NP.
Data shown are mean percentages of triplicates of infected cells FSD.
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allows this variant to successfully compete with the UV-
inactivated ARM53b for receptor binding. Blocking of DG
(+/) and DG (/) ES cells with an excess of UV-
inactivated WE2.2 significantly blocked the subsequent
infection with WE2.2, but not ARM53b and its derived
variants PBL364, CD4-1, and CD8-4 (Fig. 6). These find-
ings suggest that ARM53b, PBL364, CD4-1, and CD8-4
use at least partially identical receptor molecules to infect
DG (/) ES cells, which are distinct from the receptor(s)
used by WE2.2.
The receptors for LCMV ARM53b and WE2.2 on DG (/)
ES cells are proteins or protein-bound entities
To analyze the biochemical nature of the receptors for
LCMV ARM53b and WE2.2 on DG (/) ES cells, we
used the FACS-based virus-cell binding assay described by
Borrow and Oldstone (1992). DG (/) ES cells were
incubated with biotinylated virus and bound virus subse-
quently detected by flow cytometry. The specificity of virus
binding was confirmed by a competition assay with unbio-
tinylated virus (Fig. 7A). In an additional control experi-
ment, biotinylated proteins from fractions of mock-infected
BHK21 supernatants were subjected to the same purifica-
tion procedure as the virus. When tested for binding to DG
(/) cells in the flow-cytometry-based assay, these bio-
tinylated protein fractions did not show significant binding
(data not shown), further confirming the specificity of the
binding observed with biotinylated virus. To determine the
biochemical nature of the receptor(s) for ARM53b and
WE2.2 on DG (/) ES cells, we treated the cells with a
series of proteases, lipases, or glycosidases, and assessed
the effects of enzyme treatment on virus binding by flowcytometry. Treatment with the proteases trypsin and pro-
teinase K resulted in a significant reduction of subsequent
virus binding. In contrast, treatment of cells with the
phospholipases PLA2, PLC, or PLD did not have a signif-
icant effect on virus binding (Fig. 7B). Treatment with PI-
PLC, which removes glycosyl-phosphatidyl-inositol (GPI)-
anchored moieties from the cell surface, did not reduce
virus binding, indicating that the receptor for ARM53b and
WE2.2 on DG (/) ES cells is not GPIlinked (Fig. 7B).
To address the role of N-linked carbohydrates in the
binding of ARM53b and WE2.2, DG (/) ES cells were
treated with N-glycosidase A (PNGaseA), which hydro-
lyzes all types of N-glycan chains from glycopeptides. O-
glycans were removed by O-glycosidase, which hydrolyzes
Galh1-3GalNAc moieties from O-glycans. To test for the
potential involvement of specific terminal sugar groups in
virus binding, cells were treated with a series of exoglyco-
sidases: a-1-2,3 mannosidase (cleaves specifically Mana-1-
2,3R), a-N-acetyl-galactosaminase (cleaves GalNAca-1R),
a-1-2 fucosidase (cleaves Fuca-1-2R), neuraminidase
(cleaves NANAa-2-3,6,8R), and h-N-acetyl-hexosamini-
dase (cleaves GlcNAch1-2,3,4,6R). Although all these
enzymes were used at concentrations and under conditions
in which they efficiently remove the corresponding sugars
from glycopeptides (see Materials and methods), none of
the treatments resulted in a significant reduction of the
binding of either ARM53b or WE2.2 to DG (/) ES cells
(Fig. 7B). These findings indicate that the carbohydrate
moieties tested are likely not critically involved in virus
binding. However, based on the limited range of our
reagents, we cannot conclude that carbohydrate structures
not tested do not participate in the virus–receptor interac-
tion. Nevertheless, our data indicate that the alternative
receptors involved in the infection of DG (/) ES cells by
Fig. 7. The receptors for LCMVARM53b and WE2.2 on DG (/) ES cells are proteins or protein-bound entities. (A) Competition experiments to show the
specificity of binding of biotinylated virus to DG (/) ES cells: single-cell suspensions of DG (/) ES cells were preincubated with the indicated amounts
of unlabeled LCMVARM53b and WE2.2 (full symbols) or protein fractions purified from supernatants of mock-infected BHK21 cells (empty symbols). Cells
were then incubated with either biotinylated LCMVARM53b (5  107 pfu/ml) or biotinylated LCMVWE2.2 (107 pfu/ml) in the presence of the same amounts
of unlabeled competitor virus or control protein. Cell surface bound virus was detected with FITC-conjugated streptavidin. For flow cytometry, a FACSCalibur
flow cytometer was used. Data are mean percentages of infected cells (n = 3, FSD). (B) Effects of enzyme treatment of DG (/) ES cells on virus binding.
DG (/) cells were treated with the following enzymes (black bars) or the corresponding reaction buffer control (white bars): proteases: trypsin and
proteinase K (PK); phospholipases: phospholipase A2 (PLA2), phospholipase C (PLC), phospholipase D (PLD), and phosphoinositol-specific phospholipase C
(PIPLC); glycosidases: N-glycosidase A (N-Glyc), O-glycosidase (O-Glyc), a-1-2,3 mannosidase (Man), h-N-acetyl-hexosaminidase (h-NAcHex), a-N-
acetyl-galactosaminase (a-NAcGal), a-1-2 fucosidase (Fuc), and neuraminidase (Neu). Binding of biotinylated ARM53b (108 pfu/ml) or biotinylated WE2.2
(107 pfu/ml) was subsequently determined as described in (A). Data shown are mean percentages of virus binding cells of triplicate samples FSD.
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selves cell surface proteins or biochemical moieties at-
tached to proteins.Discussion
Here we investigated receptor usage by selected LCMV
isolates and make the following points. (1) LCMV immu-
nosuppressive variants show high-affinity binding to a-DG
and depend on a-DG for infection. One exception was a
variant that showed strong binding to a-DG but was not
dependent on a-DG for entry. (2) By contrast, variants of
LCMV that do not suppress the immune response either
displayed low or no binding affinity for a-DG and used
alternative receptors in addition to or instead of a-DG. (3)
For all a-DG binding variants, a-DG represents the pre-
ferred receptor in DG-expressing cells. (4) Soluble a-DG
blocked infection of these variants in DG-deficient cells,
indicating that binding of a-DG to the viral glycoprotein
(GP) at the virion surface interferes with the GP’s interac-
tion with alternative receptors. (5) Biochemical character-ization indicates that the alternative receptors for LCMVare
either protein(s) or protein-bound entities.
The use of different receptors by the same virus has been
reported for other viruses (reviewed by Baranowski et al.,
2001, 2003; Schneider-Schaulies, 2000; Wimmer, 1994)
like, for example, human immunodeficiency virus (HIV)
type 1 (Michael, 1999), adeno-associated virus (Summer-
ford et al., 1999), sindbis virus (Klimstra et al., 1998),
herpes simplex virus (Montgomery et al., 1996), and foot-
and-mouth disease virus (Neff et al., 1998). The novelty in
our studies with arenaviruses is the finding that virus–
receptor interactions of variants of the same virus species
during persistent infections allowed the generation of var-
iants that showed specific growth advantages in certain
cells, and this process resulted in distinct pathological
phenotypes and resultant disease outcomes. The organotypic
and cellular selection of LCMV variants in vivo (Ahmed
and Oldstone, 1988; Ahmed et al., 1984; Evans et al., 1994;
Oldstone et al., 1988; Sevilla et al., 2000) was influenced
primarily by virus–receptor interactions.
The cellular receptor for Old World arenaviruses like
LCMV and Lassa fever virus (LFV) is a-dystroglycan (a-
Table 2
Receptor use by the LCMV isolates tested
Isolate a-DG binding a-DG dependence Receptors used
cl-13 +++ +++ a-DG
PBL673 +++ +++ a-DG
WE54 +++ +++ a-DG
PBL364 +++  a-DG + AR1
ARM53b + + a-DG + AR1
CD41 + + a-DG + AR1
CD84 + + a-DG + AR1
WE22   AR2
AR1 represents the putative alternative receptor(s) for ARM53b, PBL364,
CD4-1, and CD8-4, and AR2 the putative receptor molecule(s) utilized by
WE2.2.
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the mouse, allowed us to dissect the role in viral pathogenesis
played by the generation of quasi-species of virus and the
interaction of such viruses with the a-DG receptor. A
consistent correlation between high a-DG binding affinity
and the immunosuppressive disease potential of the virus is
known (Sevilla et al., 2000; Smelt et al., 2001). However, for
some variants of LCMV, it was not clear whether they could
use alternative receptors in addition to or instead of a-DG
(Smelt et al., 2001). The study here addressed this issue by
analysis of receptor binding and usage for several selected
LCMV isolates. Examined were the prototypic non-immu-
nosuppressive parental virus LCMVARM53b, its immuno-
suppressive variants clone-13 (cl-13), PBL364, and PBL673,
and its non-immunosuppressive variants CD4-1, and CD8-4.
LCMVARM53b and cl-13 (Ahmed et al., 1984) differ at the
structural level by only two point mutations, K1079Q in the
viral polymerase, and F260L in the viral glycoprotein (Sal-
vato et al., 1988, 1991). Reassortants of viral genes mapped
the receptor binding and the immunosuppressive phenotype
to L or I at amino acid 260 of GP (Dockter et al., 1996; Sevilla
et al., 2000; Smelt et al., 2001). The variants PBL364 and
PBL673 were isolated from peripheral blood lymphocytes
(PBLs) of perforin ko mice persistently infected with LCMV
ARM53b for 7 months (Sevilla et al., 2000). The variants
CD4-1 and CD8-4 were isolated from CD4 and CD8 cells
from perforin ko mice after 24 days of infection with
ARM53b. Also analyzed was another pair of closely related
LCMV isolates, WE54 and WE2.2, which exhibit strikingly
different disease potentials (Sevilla et al., 2001; Teng et al.,
1996) and differ from each other by only one amino acid
exchange, S153F in GP1 (Teng et al., 1996). In adult
immunocompetent mice, WE54 causes a persistent infection
accompanied by a generalized immunosuppression, similar
to LCMV cl-13, while WE2.2 is not immunosuppressive but
easily generates an anti-viral CTL response that clears the
virus during an acute infection thereby preventing the estab-
lishment of persistent infection (Sevilla et al., 2000; Smelt et
al., 2001). In addition, when inoculated into newborn C3H/St
mice, WE2.2, but not WE54, causes growth hormone defi-
ciency syndrome, which also mapped to the S153F mutation
in GP1 (de la Torre and Oldstone, 1992; Oldstone et al., 1984;
Teng et al., 1996).
Using these LCMV viruses, we found four distinct virus–
receptor interactions (Table 2). In agreement with previous
findings, the variants cl-13, WE54, and PBL673 show high-
affinity binding to a-DG and strongly depend on a-DG for
infection. Their receptor-binding phenotype is similar to the
human pathogenic Old World arenavirus LFV and the Clade
C NewWorld arenaviruses Oliveros and Latino (Spiropoulou
et al., 2002). The similarity of the receptor-binding pheno-
types between these rather distantly related arenaviruses is
striking and suggests a strong selective pressure for high-
affinity a-DG binding in their natural rodent host species. A
novel receptor phenotype was uncovered by study of the
variant PBL364. Despite PBL364’s high binding affinity toa-DG, which was comparable to the affinities observed with
cl-13, WE54, and PBL673, and correlates with its ability to
cause a general immunosuppression and persistent infection
(Sevilla et al., 2000), this variant shows negligible depen-
dence on a-DG for infection and efficiently uses an alterna-
tive receptor for cell entry. Sequence comparison between
ARM53b and PBL364 revealed only three differences in GP1
in addition to the F260L mutation: Y60H, Q73N, and A242E
(Sevilla et al., 2002). In addition, a third receptor-binding
phenotype is represented by ARM53b and its variants CD4-1
and CD8-4, all of which contain an F at position 260 of GP1.
These three viruses bind to a-DG with a >100-fold lower
affinity and used an alternative receptor to infect DG-defi-
cient cells. However, the more efficient infection of DG (+/)
ES cells when compared to DG (/) ES cells indicated
either that a-DG represented the preferred receptor for these
variants on DG-positive cells or that a-DG somehow facil-
itates infection via the alternative receptor. Our data indicate
that binding of a-DG to the GPs of ARM53b, PBL364, CD4-
1, and CD8-4 blocks their interaction with alternative recep-
tor molecules. The efficiency of blocking by a-DG correlates
with the a-DG binding affinity of the virus and may be due to
competition for overlapping binding sites or steric hindrance.
These findings suggest that on DG-positive cells, a-DG
represents the preferred receptor for variants with a dual
receptor specificity rather than facilitates infection via alter-
native receptor(s). The fourth distinct receptor-binding pat-
tern is represented by WE2.2. LCMV WE2.2, in contrast to
its parental virus WE54, does not bind to a-DG and shows no
dependence on a-DG for cell entry and infection. This
suggests that the point mutation S153F (S: WE54, F:
WE2.2) in GP1 likely has two effects. First, a total loss of
a-DG binding, and second, the ability to recognize a novel
receptor molecule expressed on DG (/) ES cells. The loss
of a-DG binding due to the S153F amino acid exchange
likely explains the inability of WE2.2 to cause immunosup-
pression. In addition, the S153F mutation in GP1 appears to
allow WE2.2 to recognize a receptor molecule that is specif-
ically expressed on growth hormone (GH)-producing cells in
the anterior pituitary, resulting in a novel disease phenotype.
Interestingly, with the exception of their different tropism for
GH-producing cells, both WE54 and WE2.2 show a similar
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overall expression pattern of a-DG and the receptor mole-
cule(s) utilized by WE2.2.
The remarkable differences in receptor phenotypes caused
by single amino acid changes such as F260L (ARM53b/cl-
13) and S153F (WE54/WE2.2) suggest that minimal changes
in viral genomesmay lead to a shift in receptor usage for virus
entry. Single amino acid changes in surface proteins have a
major impact on receptor usage, tissue tropism, and disease
potential of other viruses, such as measles virus (Hsu et al.,
1998), Theiler’s murine encephalitis virus (McCright et al.,
1999), polio virus (Colston and Racaniello, 1995), and
influenza virus (Skehel and Wiley, 2000). Given the current
evidence for a quasi-species population structure of arenavi-
ruses (reviewed by Sevilla et al., 2002), the genetic distance
that the virus must bridge to significantly alter its receptor-
binding phenotype appears to be rather small.
It is currently not clear how many additional receptor
molecules can be used by LCMV isolates. Competition
studies with UV-inactivated virus on DG (/) cells dem-
onstrated that ARM53b and its variants PBL364, CD4-1,
and CD8-4 use at least partially identical alternative recep-
tors. In contrast, the inability of UV-inactivated ARM53b to
block infection with WE2.2 and vice versa suggests that
these viruses use distinct receptors for infection of DG
(/) ES cells. To determine the biochemical nature of the
cell surface component(s) on DG (/) ES cells to which
LCMV ARM53b and WE2.2 bind, the effect of selective
removal of different host cell membrane components on
virus binding was investigated. Treatment of DG (/) ES
cells with proteases but not phospholipases or glycosidases
significantly reduced binding of LCMV ARM53b and
WE22, indicating that the cellular receptors for these iso-
lates are either protein(s) or protein-bound entities.
The evolution and selection of viruses have long held the
interest of virologists (reviewed by Baranowski et al., 2001,
2003; Woolhouse et al., 2002). Analysis of these events for
arenaviruses and especially LCMV in its natural host adds to
growing knowledge in this area due to three factors: the
ability to manipulate the LCMV genome (reviewed by Lee
and de la Torre, 2002), the use of genetics in its natural
murine host (reviewed by Rall and Oldstone, 1997), and the
accumulated data on the immunobiology and pathogenesis
of LCMV infection (reviewed by Oldstone, 2002). In
addition, the data derived may have implications for under-
standing and treatment of the Old World and New World
arenaviruses that cause hemorrhagic fevers in humans, an
important medical problem.Materials and methods
Proteins, antibodies, cell cultures, and viruses
For biotinylation, a-DG (purified from rabbit skeletal
muscle) was dialyzed against a reaction buffer (0.1 MNaHCO3, 100 mM NaCl, pH 8.3) and exposed to 1 mM
NHS-X-biotin (Calbiochem) diluted in cold reaction buffer.
The reagent was applied for 20 min on ice with gentle
shaking, after which free biotin was quenched by adding
glycine, pH 8.0, in a final concentration of 50 mM.
Biotinylated a-DG was dialyzed against PBS and biotiny-
lation verified by Western-blot using streptavidin coupled
to peroxidase (Pierce) for detection. Protein concentrations
were determined by the method of Bradford. The fusion
protein DGFc1 represents a transcriptional fusion of amino
acids 30–181 of a-DG with the Fc moiety of human IgG1
and was expressed and purified from HEK293T cells as
described (Kunz et al., 2001). Monoclonal antibodies
(mAb) 113 (anti-LCMV NP) and 83.6 (anti-LCMVGP2)
have been described (Buchmeier et al., 1981; Weber and
Buchmeier, 1988). HRP-conjugated anti-mouse IgG was
from Pierce Chemical Co., Rockford, IL. DG (+/) and
DG (/) embryonic stem (ES) cells, and 3T6 mouse
fibroblasts cells were maintained as described (Cao et al.,
1998). Origin, passage, and characteristics of LCMV
ARM53b, cl-13, WE54, and WE2.2 have been described
elsewhere (Ahmed et al., 1984; Dutko and Oldstone, 1983;
Teng et al., 1996). The variants PBL364 and PBL673 have
been isolated from peripheral blood lymphocytes (PBLs) of
perforin (/) mice, infected at birth with 103 pfu
ARM53b at 7 months postinfection as described (Sevilla
et al., 2000). The variants CD4-1 and CD8-4 were isolated
from CD4+ and CD8+ cells of the same 24 days postinfec-
tion (Sevilla et al., 2000). Seed stocks of all viruses were
prepared by growth in BHK-21 cells. Purified virus stocks
were produced and virus titers determined as described
(Dutko and Oldstone, 1983).
Detection of LCMVGP and LCMV NP in ELISA
For the determination of GP/NP ratios in LCMV
variants, three independent preparations of renografin-
purified viruses were analyzed for each variant studied.
Purified viruses were coated in triplicate wells in 96-well
EIA/RIA high-bond microtiter plates (Corning) for 2 h at
6 jC and nonspecific binding blocked with 1% (wt/vol)
BSA/PBS. For the detection of NP, immobilized viruses
were fixed with 2% (wt/vol) paraformaldehyde in PBS,
washed three times in PBS, and treated with 0.1% (wt/
vol) Triton X-100 for 10 min at room temperature. mAbs
83.6 (anti-LCMVGP2) and 113 (anti-LCMV NP) were
applied in 1: 100 dilution for 2 h at 6 jC and detected
with peroxidase-conjugated anti-mouse IgG (1: 1000) in
a color reaction using 2,2Vazino-bis(3-ethylbenzthiazoline-
6-sulfonic acid) (ABTS) substrate. OD (405) was mea-
sured with an ELISA reader. For the determination of
specific binding, background binding to BSA was sub-
tracted. GP2/NP ratios were calculated for each prepara-
tion individually: the average OD (405) of the GP2
signal was divided by the average OD (405) of the NP
signal.
ogy 3Immunoblotting
Purified viruses were lysed in preheated (95 jC) SDS-
PAGE sample buffer: 2% (wt/vol) SDS, 50 mM Tris–HCl,
pH 6.8, 100 mM DTT. Proteins were separated by gel
electrophoresis and transferred to nitrocellulose. After
blocking in 5% (wt/vol) skim milk powder in PBS, mem-
branes were incubated with the primary antibody mAb 83.6
anti-LCMVGP2 in a dilution of 1:1000 in 2% (wt/vol) skim
milk powder, PBS for 12 h at 6 jC. After several washes in
PBS, 0.1% (wt/vol) Tween 20 (PBST), the secondary
antibody, goat anti-mouse IgG coupled to peroxidase was
applied 1: 5000 in PBST for 1 h at room temperature. Blots
were developed by enhanced chemiluminescence (ECL)
using Super Signal West Pico ECL Substrate (Pierce) and
signals were recorded on autoradiographic film (Kodak,
Rochester, N.Y.).
Binding of biotinylated a-DG and to LCMV variants
a-DG purified from rabbit skeletal muscle was biotiny-
lated with the reagent NHS-X-biotin as described above. To
test for biological activity of biotinylated a-DG, 105 pfu of
LCMVARM and cl-13 was incubated with 0, 1, 2, 5, 10, and
20 nM of either biotinylated or unmodified a-DG for 2 h on
ice. The inoculum was then added to 105 CHOK1 cells
cultured in a M24 plate (MOI = 1) for 45 min. Cells were
washed and incubated for 16 h. LCMVinfection was assessed
by immunofluorescence staining for LCMV NP as described
(Cao et al., 1998). Cells (100) were counted and NP-positive
cells scored (n = 3F SD). As the neutralization of LCMV cl-
13 infection of biotinylated a-DG was found to be not
significantly different from unmodified a-DG, the virus-
binding properties of a-DG are apparently not affected by
biotinylation. To test binding to biotinylated a-DG, LCMV
variants were immobilized in microtiter plates and incubated
with the indicated concentrations of biotinylated a-DG.
Bound biotinylated a-DG was detected with peroxidase-
conjugated streptavidin in a color reaction using ABTS
substrate. OD (405) was recorded in an ELISA reader. For
the determination of specific binding, background binding to
BSAwas subtracted.
Infection of embryonic stem (ES) cells
DG (/) and DG (+/) ES cells were plated in gelatin-
pretreated 96-well plates in a density of 104 cells/well. AdV-
mediated gene transfer of wild-type DG and the DG deletion
mutant DGHwas performed as described in Cao et al. (1998).
After 48 h, LCMV was added to AdV-transfected DG (/)
ES cells as well as untreated control DG (/) and DG (+/)
cells at a MOI of 1 and incubated for 1 h at 37 jC. The viral
particles were removed, cells washed twice with DMEM, and
fresh medium added. After the time points indicated, infected
cells were quantified by immunofluorescence staining for
LCMV NP as described (Smelt et al., 2001).
S. Kunz et al. / Virol442Neutralization of LCMV infection with a-DG
Neutralization of LCMV infection with a-DG was per-
formed as described in Cao et al. (1998). 3T6 mouse
fibroblasts, DG (/), or DG (+/) ES cells were cultured
in M96 tissue culture plates (2  104 cells/well). The
LCMV variants (MOI = 1 for the infection of 3T6 cells
and MOI = 3 for the infection of DG (/) and DG (+/)
ES cells) were incubated with the indicated concentrations
of a-DG for 1 h on ice. As a control, the nonbinding a-DG-
Fc fusion protein DGFc1 (Kunz et al., 2001) was used. The
inoculum was added to the target cells for 45 min at 37 jC,
5% (vol/vol) CO2. Cells were washed and incubated for 16
h. LCMV infection was assessed by immunofluorescence
staining for LCMV NP. For infection of 3T6 and DG (+/)
ES cells, 100 cells were counted and LCMV NP-positive
cells scored. In case of infected DG (/) ES cells, 300
cells were counted.
Blocking of infection of cells with LCMV with
UV-inactivated virus
LCMV ARM53b and WE2.2 were produced in BHK
cells, purified by renografin gradient (Dutko and Oldstone,
1983), tittered on Vero cells, and UV-inactivated as de-
scribed (Bachmann et al., 1994) using 10 min of UV
irradiation for inactivation. Inactivation was verified by
the absence of LCMV NP expression in Vero cells 48 and
72 h after infection with UV-inactivated preparations
(MOI = 0, 1, 10, 100) by immunofluorescence staining as
well as plaque assay on Vero cells. As a control, we used
supernatant of mock-infected BHK21 cells that was sub-
jected to the same purification and inactivation procedures as
used for the virus. For blocking, DG (/) and DG (+/)
ESC, cultured in gelatin-coated 96-well plates (2 103 cells/
well), were incubated with 100 Al/well UV-inactivated
LCMV (108 pfu/ml in 50% OPTIMEM) or the mock-
infected supernatant control in 50% OPTIMEM for 2 h on
ice. Live LCMV (2 103 pfu; MOI = 1) was mixed with 108
pfu/ml UV-inactivated LCMVor mock-infected supernatant
control in 50% OPTIMEM in a total volume of 100 Al and
the inoculum added to the cells. After 45 min of incubation at
37 jC, 5% CO2, supernatants were removed, cells washed
four times with medium (w/o ESGRO) and incubated for 16
h. For immunofluorescence staining, the medium was re-
moved and cells fixed in 2% formaldehyde/PBS for 10 min
at room temperature, wells were washed three times with
PBS, cells blocked with 1% (vol/vol) FBS, PBS, and per-
meabilized with 1% (vol/vol) FBS, 0.1% (wt/vol) saponin,
PBS for 15 min at room temperature. MAb 1-1-3 was diluted
1:100 in PBS/1% FBS/0.1% saponin and incubated for 45
min at room temperature. Secondary antibody (goat anti-
mouse IgG-FITC, 1: 40 in 1% (vol/vol) FBS, 0.1% (wt/vol)
saponin) PBS was applied for 45 min in the dark. For
quantitative assessment of infection in DG (/) ES cells,
triplicates of 500 cells were counted and LCMVNP-positive
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cells were counted.
Binding of biotinylated virus to ES cells
For biotinylation of LCMV ARM53b and WE2.2, we
used a modified version of the protocol described by
Borrow and Oldstone (1992). Briefly, purified virus was
dialyzed against reaction buffer (0.1 M NaHCO3, 100 mM
NaCl, pH 8.0) and biotinylation was accomplished by
addition of 1 mM NHS-X-biotin (final concentration) from
a 100 mM stock solution in water-free DMSO. After 20 min
on ice under gentle shaking, another 1 mM NHS-X-biotin
(final concentration) was added and the reaction let go for
another 20 min. After a total reaction time of 40 min, the
reaction was quenched by adding cold 50 mM glycine (final
concentration) pH 8.0 for 10 min. Virus was dialyzed
against PBS and infectivity checked by plaque assay on
Vero cells. Only biotinylated virus retaining >30% of
infectivity was used in experiments. The extent of biotiny-
lation of the virus is tested by ELISA using POD-conjugated
streptavidin for detection.
Binding assay (modified from Borrow and Oldstone, 1992)
DG (/) ES cells were cultured in gelatin-coated M6
tissue culture plates (2  105 cells/well) for 48 h, washed
three times with PBS, and detached using enzyme-free
dissociation solution (Sigma) for 5–10 min at 37 jC. Cells
were removed using a cell scraper, dissociated by titration
(five times) with a blue tip, and centrifuged for 5 min at
1200 rpm. The pellet was resuspended in 1% (vol/vol) FBS/
0.1% (wt/vol) sodium azide/PBS (FACS-buffer) and
blocked for 15 min on ice. Cells (5  104) were transferred
to each well of M96 plates, centrifuged for 5 min at 1200
rpm, and resuspended in 50 Al FACS buffer containing
biotinylated LCMV ARM53b (108 pfu/ml) or LCMV
WE2.2 (107 pfu/ml). Incubation was for 2 h on ice under
shaking. After two rapid wash-steps in FACS-buffer at 4 jC,
cells were re-suspended in 4% PFA and fixed for 10 min on
ice. After three washes in FACS buffer, biotinylated virus
was detected by adding FITC-conjugated streptavidin (1:
100 in FACS-buffer) for 45 min in the dark. After three
wash-steps in FACS buffer, cells were fixed with 4% (wt/
vol) paraformaldehyde, PBS for 10 min at room tempera-
ture, washed three times with PBS, and analyzed with a
FACSCalibur flow cytometer (Becton Dickinson, San Jose
CA) using Cell Quest software. Specificity of binding was
demonstrated in two ways: (1) by the ability of unlabeled
virus (but not proteins from fractions of mock-infected
BHK21 supernatants that were subjected to the same puri-
fication procedure as the virus) to block binding of bio-
tinylated virus to DG (/) ES cells. For competition
experiments, cells were preincubated with 0, 0.1, 0.5, 1,
and 5  108 pfu/ml of unlabeled virus for 1 h on ice.
Biotinylated LCMV ARM53b (5  107 pfu/ml) or LCMV
WE2.2 (107 pfu/ml) was added in the presence of the sameconcentrations of unlabeled virus. For the control experi-
ments, we used the corresponding dilutions of purified
supernatants of mock-infected BHK cells for the competi-
tion assay. (2) We biotinylated proteins from fractions of
mock-infected BHK21 supernatants that were subjected to
the same purification procedure as the virus using the
protocol described above. When tested for binding to DG
(/) cells in the flow-cytometry-based assay, these bio-
tinylated protein fractions did not show significant binding,
indicating that the specific binding observed with biotiny-
lated virus was due to binding of the virus and not a co-
purified protein component present in the viral preparation.
Enzyme treatment of DG (/) ES cells
Single-cell suspensions of DG (/) ES cells were
prepared as described above. For enzyme treatment, 105
cells were transferred to M96 plates (triplicates) and washed
twice in HBSS. Enzyme treatments of cells in suspension
were carried out as described by Borrow and Oldstone
(1992).
Proteases
Cells were resuspended in 100 Al HBSS, pH 7.5, con-
taining 10 Ag/ml proteinase K from T. album (Roche) or 10
Ag/ml trypsin from bovine pancreas (Sigma). After incuba-
tion for 1 h at 37 jC, 10% (vol/vol) FBS was added to
quench proteases. Cells were washed twice in FACS-buffer
and subjected to the binding assay with biotinylated virus.
Phospholipases
Cells were resuspended in 100 Al HBSS, pH 8.0, con-
taining 10 U/ml Phospholipase A2 (PLA2) from Streptomy-
ces violaceroruber (Sigma), 100 Al HBSS, pH 7.3
containing 10 U/ml phospholipase C (PLC) from Clostrid-
ium perfringens (Sigma), 100 Al HBSS, pH 6.5, containing
100 U/ml phospholipase D (PLD) from Streptomyces spe-
cies, 100 Al HBSS, pH 8.0, containing 100 U/ml PI-specific
phospholipase C (PI-PLC) from Bacillus cereus.
Endoglycosidases
Cells were resuspended in 100 Al of 1% (wt/vol) BSA,
HBSS, pH 7.5, containing 1 mU/ml N-glycosidase A from
sweet almonds (PNGaseA, Roche), 1% (wt/vol) BSA,
HBSS, pH 7.5, containing 10 mU/ml O-glycosidase from
Diplococcus pneumoniae (Roche).
Exoglycosidases
Cells were resuspended in 100 Al of 1% (wt/vol) BSA,
50 mM HEPES, 5 mM CaCl2, pH 6.5, containing 10 U/ml
a-1-2,3 mannosidase from Xanthomonas manihotis (New
England Biolabs, NEB), 1% (wt/vol) BSA, HBSS, pH 7.5,
containing 10 U/ml a-N-acetyl-galactosaminase from E.
coli (NEB), 1% (wt/vol) BSA, HBSS, pH 7.5, containing
10 U/ml a-1-2 fucosidase from X. manihotis (NEB), 1%
(wt/vol) BSA, HBSS, pH 6.5, containing 100 U/ml neur-
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BSA, HBSS, pH 6.5, containing 100 U/ml h-N-acetyl-
hexosaminidase from Streptomyces plicatus (NEB). In con-
trol samples, cells were incubated with buffer only. Enzyme
treatment was for 1 h at 37 jC if not indicated otherwise.
Cells were then washed twice in FACS buffer and cell
viability checked by staining with 7-amino-actinomycin (7-
AAD) (BD Biosciences). Briefly, 10 Al of cell suspension
was removed from each sample and 1 Al of 1: 10 dilution of
7-AAD stock added to sample. After incubation for 10 min
at room temperature, cells were washed twice in FACS
buffer and examined by fluorescence microscopy using a
Zeiss Axiovert S100 microscope (Carl Zeiss Inc. Thorn-
wood, NY) fitted with a 20 objective, an AxioCam digital
camera, and an automated stage. Triplicates of 100 cells in
phase were counted and cells showing red fluorescence
scored as dead or dying. The percentage of viable cells
was calculated accordingly. Cell viability after treatment
with enzyme/without enzyme was as follows: PLA2: 81%
(F9)/88 (F11), PLC: 76% (F12)/86 (F9), PLD: 64%
(F13)/80 (F12), PI-PLC: 80% (F12)/92 (F9), PNGaseA:
71% (F9)/69 (F11), O-glycanase 92% (F10)/96 (F8), a-1-
2,3 mannosidase: 65% (F7)/71 (F11), a-N-acetyl-galacto-
saminase: 89% (F9)/85 (F10), a-1-2 fucosidase: 91%
(F8)/88 (F12), neuraminidase: 61% (F9)/62 (F9), and
h-N-acetyl-hexosaminidase: 71% (F6)/62 (F9); proteinase
K: 72 (F11); Trypsin: 79 (F6). For subsequent binding to
biotinylated virus, 5  104 live cells were transferred to
each well of M96 plates, centrifuged for 5 min at 1200 rpm,
and incubated with either biotinylated LCMVARM53b (108
pfu/ml) or biotinylated LCMVWE2.2 (107 pfu/ml) in FACS
buffer, and incubated for 2 h on ice under shaking. After two
rapid wash-steps in FACS-buffer at 4 jC, cells were re-
suspended in 4% PFA and fixed for 10 min on ice, and
bound virus detected by flow cytometry as described above.Acknowledgments
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